000280: OUTCOME OF PATIENTS WITH MUCINOUS OVARIAN CARCINOMA

Objective: Mucinous epithelial carcinoma of the ovary (MEOC) is often difficult to differentiate from colon adenocarcinoma. Adjuvant chemotherapy is chosen based on EOC guidelines, and often bears platinum resistance. The aim of our study was to examine the clinical outcome of MEOC patients treated with various adjuvant chemotherapy regimens. Methods: Medical records of MEOC patients from 1983-2000 were reviewed. Survival distributions were calculated using the Kaplan Meier and comparisons of survival using the log-rank test. Results: Forty-one medical records were available. Twenty-seven patients (66%) were optimally cytoreduced. Nine cases (22%) had pathologic features consistent with colon carcinoma. Fourteen were early stage, 27 advanced stage. Thirty-two patients received chemotherapy, 4 XRT and 6 P32 in the adjuvant setting. Fifteen different chemotherapy regimens were given. The overall median survival for the entire group was 14 months of 32 patients receiving chemotherapy, 8 had CR, 11 had PD, 8 progressed, and 2 died during adjuvant treatment (response unknown in 3). Twenty-three patients receiving a platinum- containing regimen had a median survival of 14 months versus 5-FU containing regimen had a median survival of 7 months for 5 patients. In comparison, GOG Protocol 158 (70% serous, 3% mucinous), overall survival was 57.4 months. At last follow-up, 4 died NED, 32 died of disease, and 5 died with disease status unknown. Conclusion: Our data demonstrates that MEOC patients treated with platinum-based regimens have a better overall survival than those treated with 5-FU containing regimens. Historic data shows mucinous tumors do poorly as compared to serous tumors.